ReviewEuropean radiology experimental2020
PET/CT imaging for tumour response assessment to immunotherapy: current status and future directions.
Review in European radiology experimental, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Mapping the research landscape of PET/CT in lymphoma: insights from a bibliometric analysis.Frontiers in oncology · 2025Pooled it
- A systematic review of gastritis as an immune-related adverse event in clinical interventions.Human vaccines & immunotherapeutics · 2024Pooled it
- Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study.Journal for immunotherapy of cancer · 2022Trial
- PET/CT imaging for assessment of tumor immunotherapy response: a new perspective on tumor metabolic reprogramming and immune escape.La Radiologia medica · 2026Review
- Imaging Immunotherapy.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2026Review
- Advancing In Vivo Detection of T-Cell Function: Development and Preclinical Evaluation ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
- Metastasis of Squamous Cell Carcinoma of the Larynx to the Right Adrenal Gland-A Case Report.Clinics and practice · 2025Article
- MRI features and preliminary diagnostic assessment using large language models of cystic tumor progression mimicking radiation necrosis in brain metastasis patients treated with immunotherapy: case report.Frontiers in immunology · 2025Article
- Complex immunotherapy-mediated response patterns depicted on serialAsia Oceania journal of nuclear medicine & biology · 2025Article
- A Wireless, Multicolor Fluorescence Image Sensor Implant for Real-Time Monitoring in Cancer Therapy.IEEE journal of solid-state circuits · 2024Article
- Organ-specific accuracy of [Japanese journal of radiology · 2024Article
- Nonoperative Management of dMMR/MSI-H Colorectal Cancer following Neoadjuvant Immunotherapy: A Narrative Review.Clinics in colon and rectal surgery · 2023Review
- Metabolic patterns on [European journal of nuclear medicine and molecular imaging · 2023Article
- FDG-PET/CT in the Monitoring of Lymphoma Immunotherapy Response: Current Status and Future Prospects.Cancers · 2023Review
- Review
- Diagnostic impact ofClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022Article
- Anti-PD-1: When to Stop Treatment.Current oncology reports · 2022Review
- Radionuclide Imaging of Cytotoxic Immune Cell Responses to Anti-Cancer Immunotherapy.Biomedicines · 2022Review
- Targeted next-generation sequencing of circulating free DNA enables non-invasive tumor detection in myxoid liposarcomas.Molecular cancer · 2022Article
- Hepatocellular carcinoma with complete response to the immunotherapy: the oncologist's dilemma.Hepatobiliary surgery and nutrition · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent immunotherapeutic approaches have evolved as powerful treatment options with high anti-tumour responses involving the patient's own immune system. Passive immunotherapy applies agents that enhance existing anti-tumour responses, such as antibodies against immune checkpoints. Active immunotherapy uses agents that direct the immune system to attack tumour cells by targeting tumour antigens. Active cellular-based therapies are on the rise, most notably chimeric antigen receptor T cell therapy, which redirects patient-derived T cells against tumour antigens. Approved treatments are available for a variety of solid malignancies including melanoma, lung cancer and haematologic diseases. These novel immune-related therapeutic approaches can be accompanied by new patterns of response and progression and immune-related side-effects that challenge established imaging-based response assessment criteria, such as Response Evaluation Criteria in Solid tumours (RECIST) 1.1. Hence, new criteria have been developed. Beyond morphological information of computed tomography (CT) and magnetic resonance imaging, positron emission tomography (PET) emerges as a comprehensive imaging modality by assessing (patho-)physiological processes such as glucose metabolism, which enables more comprehensive response assessment in oncological patients. We review the current concepts of response assessment to immunotherapy with particular emphasis on hybrid imaging with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.